You are here: Lenkinski Lab»Overview


There are several major goals of the research program. The first is the development, validation and application of Magnetic Resonance Spectroscopic (MRS) and Multi-nuclear Imaging methods for the study of human disease. This program is aimed at understanding how the metabolic information derived from these methods can aid in the diagnosis, staging and treatment of a variety of pathologies. Current applications involve brain tumors, breast cancer, prostate cancer and renal function. This work involves basic research, translational, and clinical investigations.

A second part of this program is the development of targeted molecular imaging agents. This work spans chemical conjugation, basic theoretical treatments of effect size. A major aim of this research is the characterization of these agents in model systems. At present a major focus is on lanthanide based MRI relaxation and shift reagents and their conjugation to low-molecular weight ligands and their analgous PET tracers.. A particular example is the development of targeted agents for imaging of micro-calcifications in human breast cancer.

We are also involved in the development and validation of a number of quantitative MRI methods. These include Arterial Spin Labeling (ASL), Dynamic Contrast Enhanced MRI (DCEMRI), and Diffusion Weighted MRI, DWMRI for the study of human disease.